In this review:
The increased prevalence of weight gain and obesity has far-reaching consequences for individuals, society, and the economy. Liraglutide 3 mg (Saxenda®), a glucagon-like peptide-1 analogue, is indicated for weight management, as an adjunct to a reduced-calorie diet and increased physical activity, in adult patients with obesity or who are overweight with at least one weight-related comorbidity. This review focusses on the key characteristics of liraglutide 3 mg and provides a summary of the key data from the SCALE clinical trial program in individuals. This review is sponsored by an educational grant from Novo Nordisk.
Please login below to download this issue (PDF)